Illumina (NASDAQ:ILMN) Price Target Raised to $235.00 at Argus

Illumina (NASDAQ:ILMN) had its price objective boosted by analysts at Argus from $180.00 to $235.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the life sciences company’s stock. Argus’ price objective suggests a potential upside of 9.77% from the stock’s current price.

Several other research firms have also recently weighed in on ILMN. Royal Bank Of Canada boosted their price objective on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Piper Sandler restated an “overweight” rating and issued a $225.00 target price (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Finally, Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $191.31.

Illumina Trading Up 0.4%

Illumina stock opened at $214.08 on Thursday. Illumina has a one year low of $88.00 and a one year high of $231.81. The business’s fifty day moving average is $196.70 and its 200 day moving average is $157.87. The stock has a market capitalization of $32.33 billion, a PE ratio of 39.90, a price-to-earnings-growth ratio of 2.93 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.Illumina’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts predict that Illumina will post 5.36 EPS for the current year.

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,799,688 shares of company stock valued at $379,517,231. 2.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Illumina

Several hedge funds and other institutional investors have recently modified their holdings of ILMN. Empowered Funds LLC grew its holdings in Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC bought a new position in shares of Illumina during the 2nd quarter valued at approximately $621,000. CW Advisors LLC purchased a new stake in Illumina in the 2nd quarter worth approximately $275,000. Marshall Wace LLP raised its stake in Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after acquiring an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC boosted its position in shares of Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.